Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B

Pietro Lampertico, Mauro Vigan, Floriana Facchetti, Federica Invernizzi, Adriana Aroldi, Giovanna Lunghi, Pier Giorgio Messa, Massimo Colombo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background. To assess the long-term effectiveness and safety of adefovir (ADV) plus lamivudine (LMV) in LMV-resistant (R) kidney transplants with chronic hepatitis B, 11 such patients were treated with add-on ADV.Methods. Serum alanine aminotransferase, renal function and serum hepatitis B virus (HBV) DNA levels were assessed every 3 months; ADV mutations were searched for by INNO-LiPA HBV DR v2 assay.Results. During 36 months (12-48), nine patients cleared serum HBV DNA with a 3-year cumulative virological response rate of 88%, without the emergence of ADV mutations. ADV dose was reduced in six patients (55%) showing a decline of creatinine clearance, in the absence of proximal tubulopathy.Conclusions. In LMV-R kidney graft recipients, long-term add-on therapy with ADV is efficacious and safe with timely adaptation of ADV dose.

Original languageEnglish
Pages (from-to)2037-2041
Number of pages5
JournalNephrology Dialysis Transplantation
Volume26
Issue number6
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Lamivudine
Chronic Hepatitis B
Transplants
Kidney
Hepatitis B virus
Therapeutics
Serum
Mutation
DNA
adefovir
Alanine Transaminase
Creatinine
Safety

Keywords

  • adefovir dipivoxil
  • hepatitis B virus
  • lamivudine-resistance
  • renal transplantation

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

@article{099acf59da7048408c6cfd011b384689,
title = "Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B",
abstract = "Background. To assess the long-term effectiveness and safety of adefovir (ADV) plus lamivudine (LMV) in LMV-resistant (R) kidney transplants with chronic hepatitis B, 11 such patients were treated with add-on ADV.Methods. Serum alanine aminotransferase, renal function and serum hepatitis B virus (HBV) DNA levels were assessed every 3 months; ADV mutations were searched for by INNO-LiPA HBV DR v2 assay.Results. During 36 months (12-48), nine patients cleared serum HBV DNA with a 3-year cumulative virological response rate of 88{\%}, without the emergence of ADV mutations. ADV dose was reduced in six patients (55{\%}) showing a decline of creatinine clearance, in the absence of proximal tubulopathy.Conclusions. In LMV-R kidney graft recipients, long-term add-on therapy with ADV is efficacious and safe with timely adaptation of ADV dose.",
keywords = "adefovir dipivoxil, hepatitis B virus, lamivudine-resistance, renal transplantation",
author = "Pietro Lampertico and Mauro Vigan and Floriana Facchetti and Federica Invernizzi and Adriana Aroldi and Giovanna Lunghi and Messa, {Pier Giorgio} and Massimo Colombo",
year = "2011",
month = "6",
doi = "10.1093/ndt/gfr174",
language = "English",
volume = "26",
pages = "2037--2041",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B

AU - Lampertico, Pietro

AU - Vigan, Mauro

AU - Facchetti, Floriana

AU - Invernizzi, Federica

AU - Aroldi, Adriana

AU - Lunghi, Giovanna

AU - Messa, Pier Giorgio

AU - Colombo, Massimo

PY - 2011/6

Y1 - 2011/6

N2 - Background. To assess the long-term effectiveness and safety of adefovir (ADV) plus lamivudine (LMV) in LMV-resistant (R) kidney transplants with chronic hepatitis B, 11 such patients were treated with add-on ADV.Methods. Serum alanine aminotransferase, renal function and serum hepatitis B virus (HBV) DNA levels were assessed every 3 months; ADV mutations were searched for by INNO-LiPA HBV DR v2 assay.Results. During 36 months (12-48), nine patients cleared serum HBV DNA with a 3-year cumulative virological response rate of 88%, without the emergence of ADV mutations. ADV dose was reduced in six patients (55%) showing a decline of creatinine clearance, in the absence of proximal tubulopathy.Conclusions. In LMV-R kidney graft recipients, long-term add-on therapy with ADV is efficacious and safe with timely adaptation of ADV dose.

AB - Background. To assess the long-term effectiveness and safety of adefovir (ADV) plus lamivudine (LMV) in LMV-resistant (R) kidney transplants with chronic hepatitis B, 11 such patients were treated with add-on ADV.Methods. Serum alanine aminotransferase, renal function and serum hepatitis B virus (HBV) DNA levels were assessed every 3 months; ADV mutations were searched for by INNO-LiPA HBV DR v2 assay.Results. During 36 months (12-48), nine patients cleared serum HBV DNA with a 3-year cumulative virological response rate of 88%, without the emergence of ADV mutations. ADV dose was reduced in six patients (55%) showing a decline of creatinine clearance, in the absence of proximal tubulopathy.Conclusions. In LMV-R kidney graft recipients, long-term add-on therapy with ADV is efficacious and safe with timely adaptation of ADV dose.

KW - adefovir dipivoxil

KW - hepatitis B virus

KW - lamivudine-resistance

KW - renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=79958111465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958111465&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfr174

DO - 10.1093/ndt/gfr174

M3 - Article

C2 - 21486869

AN - SCOPUS:79958111465

VL - 26

SP - 2037

EP - 2041

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 6

ER -